885102-34-1

Basic information

• Product Name: tert-butyl 3-methyl-4-oxopyrrolidine-1-carboxylate
• Synonyms: tert-butyl 3-methyl-4-oxopyrrolidine-1-carboxylate
• CAS NO: 885102-34-1
• Molecular Weight: 199.25
• Mol File: 885102-34-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-methyl-4-oxopyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-methyl-4-oxopyrrolidine-1-carboxylate(885102-34-1)
• EPA Substance Registry System: tert-butyl 3-methyl-4-oxopyrrolidine-1-carboxylate(885102-34-1)

Safety Data

• Hazardous Substances Data: 885102-34-1(Hazardous Substances Data)

Upstream product

• 101385-93-7 3-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1107658-75-2 tert-butyl 3-hydroxy-4-methylpyrrolidine-1-carboxylate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 1107658-75-2 tert-butyl trans-3-hydroxy-4-methylpyrrolidine-1-carboxylate 

Relevant articles and documents

Selective α-Methylation of Ketones

The convenient and scalable preparative approach for the two-step α-methylation of ketones is described. The optimized protocols for regioselective preparation of enaminones with further diastereoselective and functional groups tolerant hydrogenation to α-methylketones are developed. The scope and limitations of the proposed methodology are discussed. The advantages compared to known procedures are demonstrated. The unexpected role of acetone in the hydrogenation is suggested. The evaluation of the method for both early building block synthesis and late-stage CH-functionalization is shown. The elaborate procedures' preparability and scalability are demonstrated by the synthesis of several α-methyl ketones up to 100 g amount.

1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.